PROTALIX BIOTHERAPEUTICS INC (PLX) competitors & alternatives
Health Care · NYSE American
PROTALIX BIOTHERAPEUTICS INC (PLX)'s top competitors and alternatives — its most similar public companies — include AMYLYX PHARMACEUTICALS INC (AMLX), SPRUCE BIOSCIENCES INC (SPRB), BioMarin Pharmaceutical (BMRN), DENALI THERAPEUTICS INC (DNLI), TRAVERE THERAPEUTICS INC (TVTX), LARIMAR THERAPEUTICS INC (LRMR), ROCKET PHARMACEUTICALS INC (RCKT), PTC THERAPEUTICS INC (PTCT), XOMA ROYALTY CORP (XOMA), Insmed (INSM), Jazz Pharmaceuticals (JAZZ) and Ultragenyx (RARE). These are PROTALIX BIOTHERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PLX competitors & alternatives
-
AMYLYX PHARMACEUTICALS INCAMLXHealth Care
Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric…
$17.70 (as of 2026-07-22) · market cap $2.0B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
BioMarin PharmaceuticalBMRNHealth Care
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene…
$58.40 (as of 2026-07-22) · market cap $11.3B
-
DENALI THERAPEUTICS INCDNLIHealth Care
Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the…
$23.64 (as of 2026-07-22) · market cap $3.7B
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
-
LARIMAR THERAPEUTICS INCLRMRHealth Care
Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the…
$4.02 (as of 2026-07-22) · market cap $418M
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
XOMA ROYALTY CORPXOMAHealth Care
A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights…
$40.17 (as of 2026-07-21) · market cap $710M
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
Not quite? Describe exactly what you want →
Peers are PROTALIX BIOTHERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: PROTALIX BIOTHERAPEUTICS INC (PLX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.